BridgeBio Pharma Inc. (BBIO)’s price-to-cash and price-to-free cash flow ratios

As of close of business last night, BridgeBio Pharma Inc.’s stock clocked out at $13.66, down -0.36% from its previous closing price of $13.71. In other words, the price has decreased by -$0.05 from its previous closing price. On the day, 1213160 shares were traded. BBIO stock price reached its highest trading level at $14.41 during the session, while it also had its lowest trading level at $13.54.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.



To gain a deeper understanding of BBIO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.70 and its Current Ratio is at 5.70.

Upgrades & Downgrades

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 17 when Kumar Neil sold 51,552 shares for $14.01 per share. The transaction valued at 722,218 led to the insider holds 4,813,197 shares of the business.

STEPHENSON BRIAN C sold 24,424 shares of BBIO for $342,168 on May 17. The Secretary, Treasurer & CFO now owns 36,408 shares after completing the transaction at $14.01 per share. On May 03, another insider, Kumar Neil, who serves as the CEO and President of the company, sold 120,000 shares for $14.18 each. As a result, the insider received 1,701,744 and left with 1,012,722 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BBIO now has a Market Capitalization of 2.16B and an Enterprise Value of 3.41B. For the stock, the TTM Price-to-Sale (P/S) ratio is 28.71. Its current Enterprise Value per Revenue stands at 43.90 whereas that against EBITDA is -10.06.

Stock Price History:

Over the past 52 weeks, BBIO has reached a high of $19.94, while it has fallen to a 52-week low of $5.74. The 50-Day Moving Average of the stock is 14.68, while the 200-Day Moving Average is calculated to be 11.39.

Shares Statistics:

It appears that BBIO traded 3.22M shares on average per day over the past three months and 1.45M shares per day over the past ten days. A total of 152.65M shares are outstanding, with a floating share count of 107.05M. Insiders hold about 4.30% of the company’s shares, while institutions hold 98.10% stake in the company. Shares short for BBIO as of Apr 27, 2023 were 14.2M with a Short Ratio of 14.20M, compared to 15.16M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.85% and a Short% of Float of 15.03%.

Earnings Estimates

As of right now, 7 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.82 for the current quarter, with a high estimate of -$0.66 and a low estimate of -$0.94, while EPS last year was -$0.07. The consensus estimate for the next quarter is -$0.77, with high estimates of -$0.59 and low estimates of -$0.9.

Analysts are recommending an EPS of between -$2.67 and -$3.75 for the fiscal current year, implying an average EPS of -$3.17. EPS for the following year is -$2.64, with 8 analysts recommending between -$1.85 and -$3.85.

Revenue Estimates

Based on 7 analysts’ estimates, the company’s revenue will be $82.95M in the next fiscal year. The high estimate is $266M and the low estimate is $10.24M. The average revenue growth estimate for next year is up 536.60% from the average revenue estimate for this year.